Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials.

Applied Science and Engineering, University of Toronto, Toronto, Ontario, Canada.
Thrombosis Research (Impact Factor: 2.43). 12/2008; 123(5):687-96. DOI: 10.1016/j.thromres.2008.09.015
Source: PubMed

ABSTRACT Minimizing bleeding and transfusion is desirable given its cost, complexity and potential for adverse events. Concerns have been heightened by recent data demonstrating that bleeding events may predict worse outcomes and by warnings about the safety of erythropoietic stimulating agents. Prior small studies suggest that antifibrinolytic agents may reduce bleeding and transfusion need in patients undergoing total hip replacement (THR) or total knee arthroplasty (TKA). However, no single study has been large enough to definitively determine if these agents are safe and effective. To address this issue we performed a systematic review of randomized trials describing the use of tranexamic acid, epsilon aminocaproic acid, or aprotinin administration in the perioperative setting.
MEDLINE, EMBASE, CINAHL and the Cochrane databases were searched for relevant trials. Two independent reviewers abstracted total blood loss, transfusion requirements, and venous thromboembolism (VTE) rates. Data were combined using the Mantel-Haenszel method and dichotomous data expressed as relative risk (RR) with 95% confidence intervals (CI).
Patients receiving antifibrinolytic agents had reduced transfusion need (RR 0.52; 95% CI, 0.42 to 0.64; P<0.00001), reduced blood loss and no increase in the risk of VTE (RR 0.95% CI, 0.80 to 1.10, I(2)=0%, P=0.531).
We conclude that antifibrinolytic agents may reduce bleeding and transfusion in patients undergoing THR or TKA who receive appropriate antithrombotic prophylaxis. There is a need for a large, adequately powered prospective study to carefully examine the safety and efficacy of these agents.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Tranexamic acid (TXA) has received extensive attention in management of blood loss in orthopedic surgeries. However, the ideal method of TXA administration is still controversial. This study aims to determine whether intraarticular injection of TXA reduces blood loss after total knee arthroplasty (TKA).
    Archives of bone and joint surgery. 09/2014; 2(3):141-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Postpartum haemorrhage (PPH) is the third-most common cause of maternal death in the United States and it is still the first prevalent cause of maternal death in developing countries. Active prevention of haemorrhage with an uterotonic or other new drugs leads to a decrease in postpartum vaginal haemorrhage. The aim of this study was to compare anti-haemorrhagic effect of Tranexamic acid (TXA) and Misoprostol for PPH.
    Journal of the Nigeria Medical Association 01/2014; 55(4):348-353.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Tranexamic acid has showed its good results reducing blood loss in total knee arthroplasties. It has also probed being cost-effective (red cell concentrate: 350 euros/ TXA vial 3, 05 euros) but it remains not being clear at what time during the surgery we have to administrate it. In this prospective, randomized study, we have investigated the effects of the use of tranexamic acid before or after inflating the tourniquet on blood loss, transfusion needs and thromboembolic complications after implanting a total knee arthroplasty. 120 patients were selected and assigned randomly in two groups: tranexamic acid employed before inflating (Group 1) or just before deflating the tourniquet (Group 2). Methods and materials: From May 2011 to May 2012, 80 patients (38 males, 42 females; aged 64-81 years, mean age 69, 2 years) underwent to a total knee replacement. All of them had moderate-severe knee osteoarthritis. They were randomized divided into Group 1 and Group 2 of 40 patients each. The patients in Group 1 received Tranexamic Acid (TXA) before inflating the tourniquet and TXA was administered on the patients in Group 2 5 minutes before deflating the tourniquet. TXA was used in both groups every 8 hours during the first three days postop. Variables under comparison included haemoglobin determinations (pre, postop and fifth days after surgery), drainage blood volume, transfusion requirements and appearance of thromboembolic complications. Results: The drainage blood loss was 364 +/-186 ml (Group 1) and 413 +/-175 ml (Group 2). The total blood loss was 573 +/-159 ml (Group 1) and 608 +/-132 (Group 2). No statistical significant differences were found in the amount of blood at the drain and on the total blood loss. The haemoglobin values did not showed statistical significant differences between groups before surgery on the postop or 5 days after the surgery. No significant difference in haemoglobin determinations (pre, postop and fifth days after surgery), drainage blood volume, transfusion requirements, deep-vein thrombosis, and pulmonary embolism was detected between the groups. One patient in group 1 received 1 unit of allogenic blood and one patient in group 2 received 3 units. No statistical significant difference was seen. Two patients in group 1 and three patients in group 2 had clinical symptoms of deep vein thrombosis. Only one patient in group 2 presented an eco-Doppler study positive for a lower limb thrombosis Conclusions: We conclude that there is no significant difference on blood loss, transfusion requirements and thromboembolic complications after performing a total knee arthroplastywhen thetranexamic acid is employed before inflating or just before releasing the tourniquet.
    International Journal of Surgery Reseach and Practice. 01/2014; 1(1):1.